Journal article
Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships
Cancer epidemiology, biomarkers & prevention, Vol.29(5), pp.1009-1018
05/2020
DOI: 10.1158/1055-9965.EPI-19-1027
PMID: 32051190
Abstract
Despite smoking being a well-established risk factor for pancreatic cancer, there is a need to further characterize pancreatic cancer risk according to lifespan smoking patterns and other smoking features, such as tobacco type. Our aim was to deeply investigate them within a large European case-control study.
Tobacco smoking habits and other relevant information were obtained from 2,009 cases and 1,532 controls recruited in the PanGenEU study using standardized tools. Multivariate logistic regression analysis was performed to evaluate pancreatic cancer risk by smoking characteristics and interactions with other pancreatic cancer risk factors. Fractional polynomials and restricted cubic splines were used to test for nonlinearity of the dose-response relationships and to analyze their shape.
Relative to never-smokers, current smokers [OR = 1.72; 95% confidence interval (95% CI), 1.39-2.12], those inhaling into the throat (OR = 1.48; 95% CI, 1.11-1.99) or chest (OR = 1.33; 95% CI, 1.12-1.58), and those using nonfiltered cigarettes (OR = 1.69; 95% CI, 1.10-2.61), were all at an increased pancreatic cancer risk. Pancreatic cancer risk was highest in current black tobacco smokers (OR = 2.09; 95% CI, 1.31-3.41), followed by blond tobacco smokers (OR = 1.43; 95% CI, 1.01-2.04). Childhood exposure to tobacco smoke relative to parental smoking was also associated with increased pancreatic cancer risk (OR = 1.24; 95% CI, 1.03-1.49). Dose-response relationships for smoking duration, intensity, cumulative dose, and smoking cessation were nonlinear and showed different shapes by tobacco type. Effect modification by family history of pancreatic cancer and diabetes was likely.
This study reveals differences in pancreatic cancer risk by tobacco type and other habit characteristics, as well as nonlinear risk associations.
This characterization of smoking-related pancreatic cancer risk profiles may help in defining pancreatic cancer high-risk populations.
Details
- Title: Subtitle
- Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships
- Creators
- Esther Molina-Montes - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), Madrid, and CIBERONC, Spain. nmalats@cnio.es memolina@cnio.esLisa Van Hoogstraten - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), Madrid, and CIBERONC, SpainPaulina Gomez-Rubio - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), Madrid, and CIBERONC, SpainMatthias Löhr - Gastrocentrum, Karolinska Institutet and University Hospital, Stockholm, SwedenLinda Sharp - Newcastle University, Institute of Health & Society, Newcastle, United KingdomXavier Molero - Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Barcelona, Universitat Autònoma de Barcelona, CIBEREHD, SpainMirari Márquez - Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), Madrid, and CIBERONC, SpainChristoph W Michalski - Department of Visceral, Vascular and Endocrine Surgery, Martin-Luther-University Halle-Wittenberg, Halle (Saale), GermanyAntoni Farré - Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, SpainJosé Perea - Department of Surgery and Health Research Institute, Fundación Jiménez Díaz, Madrid, SpainMichael O'Rorke - College of Public Health, The University of Iowa, Iowa City, IowaWilliam Greenhalf - Department of Molecular and Clinical Cancer Medicine, The Royal Liverpool University Hospital, Liverpool, United KingdomLucas Ilzarbe - Hospital del Mar-Parc de Salut Mar, Barcelona, CIBERONC, SpainAdonina Tardon - Department of Medicine, Instituto Universitario de Oncología del Principado de Asturias, Oviedo, CIBERESP, SpainThomas M Gress - Department of Gastroenterology, University Hospital of Giessen and Marburg, Marburg, GermanyVictor M Barberà - Molecular Genetics Laboratory, General University Hospital of Elche, SpainTatjana Crnogorac-Jurcevic - Barts Cancer Institute, Centre for Molecular Oncology, Queen Mary University of London, London, United KingdomLuis Muñoz-Bellvis - General and Digestive Surgery Department, Salamanca University Hospital, SpainEnrique Domínguez-Muñoz - Department of Gastroenterology, University Clinical Hospital of Santiago de Compostela, SpainJoaquim Balsells - Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Barcelona, Universitat Autònoma de Barcelona, CIBEREHD, SpainEithne Costello - Department of Molecular and Clinical Cancer Medicine, The Royal Liverpool University Hospital, Liverpool, United KingdomMar Iglesias - Hospital del Mar-Parc de Salut Mar, Barcelona, CIBERONC, SpainJorg Kleeff - Department of Visceral, Vascular and Endocrine Surgery, Martin-Luther-University Halle-Wittenberg, Halle (Saale), GermanyBo Kong - Department of Surgery, Technical University of Munich, Munich, GermanyJosefina Mora - Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, SpainDamian O'Driscoll - National Cancer Registry Ireland and HRB Clinical Research Facility, University College Cork, Cork, IrelandIgnasi Poves - Hospital del Mar-Parc de Salut Mar, Barcelona, CIBERONC, SpainAldo Scarpa - ARC-Net Centre for Applied Research on Cancer and Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, ItalyJingru Yu - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stokholm, SwedenWeimin Ye - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stokholm, SwedenManuel Hidalgo - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MassachusettsAlfredo Carrato - Department of Oncology, Ramón y Cajal University Hospital, IRYCIS, Alcala University, Madrid and CIBERONC, SpainRita Lawlor - ARC-Net Centre for Applied Research on Cancer and Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, ItalyFrancisco X Real - Epithelial Carcinogenesis Group, Madrid, Spanish National Cancer Research Centre (CNIO), Madrid, Universitat Pompeu Fabra, Departament de Ciències Experimentals i de la Salut, Barcelona, and CIBERONC, SpainNuria Malats
- Resource Type
- Journal article
- Publication Details
- Cancer epidemiology, biomarkers & prevention, Vol.29(5), pp.1009-1018
- DOI
- 10.1158/1055-9965.EPI-19-1027
- PMID
- 32051190
- NLM abbreviation
- Cancer Epidemiol Biomarkers Prev
- ISSN
- 1055-9965
- eISSN
- 1538-7755
- Publisher
- United States
- Grant note
- name: ISCII-FIS, Spain, award: #PI11/01542, #PI0902102, #PI12/01635, #PI12/00815, #PI15/01573; name: COST Action, award: #BM1204; name: EU-FP6 MolDiagPaca, award: #018771
- Language
- English
- Date published
- 05/2020
- Academic Unit
- Epidemiology; Pathology
- Record Identifier
- 9984066101602771
Metrics
22 Record Views